Anti-FDF03 Antibody, Non-Fucosylated (DX276) (CAT#: BioBet-1560ZP) Datasheet

PILRA

PILRA; paired immunoglobin-like type 2 receptor alpha; FDF03; paired immunoglobulin-like type 2 receptor alpha; cell surface receptor FDF03; inhibitory receptor PILR-alpha;

Cell signaling pathways rely on a dynamic interaction between activating and inhibiting processes. SHP-1-mediated dephosphorylation of protein tyrosine residues is central to the regulation of several cell signaling pathways. Two types of inhibitory receptor superfamily members are immunoreceptor tyrosine-based inhibitory motif (ITIM)-bearing receptors and their non-ITIM-bearing, activating counterparts. Control of cell signaling via SHP-1 is thought to occur through a balance between PILRalpha-mediated inhibition and PILRbeta-mediated activation. These paired immunoglobulin-like receptor genes are located in a tandem head-to-tail orientation on chromosome 7. This particular gene encodes the ITIM-bearing member of the receptor pair, which functions in the inhibitory role. Alternative splicing has been observed at this locus and three variants, each encoding a distinct isoform, are described. [provided by RefSeq, Jul 2008]

paired immunoglobin-like type 2 receptor alpha

Plasma membrane, Extracellular region or secreted

Diseases associated with PILRA include Herpes Simplex and Asymptomatic Neurosyphilis.

Its related pathways are Herpes simplex virus 1 infection. An important paralog of this gene is PILRB.

Paired receptors include highly related activation receptors and inhibitory receptors, which are widely involved in the regulation of the immune system. PILRA is considered to be a cell signal inhibitory receptor, which recruits cytoplasmic phosphatases such as PTPN6/SHP-1 and PTPN11/SHP-2 through its SH2 domain, and blocks signal transduction through dephosphorylation of signal molecules. (Microbial infection) As a co-receptor for herpes simplex virus 1 entry.

1.According to PubMed:10660620, N- and O-glycosylated. According to PubMed:10903717, only N-glycosylated 2.Modification sites at PhosphoSitePlus 3.Phosphorylated on tyrosine residues 4.Glycosylation at Asn100

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

DX276

Humanized

Human

The antibody is against FDF03 which is immunoregulatory receptor on myeloid cell, also known as Paired Immunoglobulin-Like type 2 Receptor (PILR). And it is used for the treatment of cancer.

Cancer

Cancer